SCHEMBL21332510

SCHEMBL21332510

CN1CCN(CCCOC2CCCCO2)C(=O)c2c1nc(Oc1cccc(OC(F)(F)F)c1)n2Cc1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ TRPC1 P48995 1/20 0.45
▸ TRPC4 Q9UBN4 1/20 0.45
▸ TRPC5 Q9UL62 1/20 0.45
▸ P2RX3 P56373 19/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21332507 0.90 TRPC1 (0.46) TRPC1TRPC4TRPC5P2RX3
SCHEMBL21332730 0.89 TRPC1 (0.44) TRPC1TRPC4TRPC5P2RX3
SCHEMBL21332602 0.88 TRPC1 (0.41) TRPC1TRPC4TRPC5P2RX3
SCHEMBL30980079 0.87 TRPC5 (0.44) TRPC1TRPC4TRPC5P2RX3
SCHEMBL21332897 0.86 TRPC1 (0.45) TRPC1TRPC4TRPC5P2RX3
SCHEMBL21332748 0.85 TRPC5 (0.60) TRPC1TRPC4TRPC5P2RX3
SCHEMBL21332584 0.84 TRPC1 (0.41) TRPC1TRPC4TRPC5P2RX3
SCHEMBL21316330 0.83 P2RX3 (0.44) TRPC5P2RX3
SCHEMBL18835175 0.78 TRPC5 (0.49) TRPC1TRPC4TRPC5P2RX3
SCHEMBL30980078 0.78 TRPC5 (0.45) TRPC1TRPC4TRPC5P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3761989-B1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF GFB ABC LLC (US) 2026-05-13 — — EP disclosed
US-12466834-B2 Imidazodiazepinediones and methods of use thereof GFB (ABC), LLC (US) 2025-11-11 — — US disclosed
CN-118908961-A Imidazodiazepine diketones and methods of use thereof 金翅雀生物公司 2024-11-08 — — CN disclosed
CN-112351781-B Imidazodiazepine diketones and methods of use thereof 金翅雀生物公司 2024-07-02 — — CN disclosed
US-20230365575-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-11-16 — — US disclosed
US-11623930-B2 Imidazodiazepinediones and methods of use thereof GOLDFINCH BIO, INC. (US) 2023-04-11 — — US disclosed
US-11623930-B2 Imidazodiazepinediones and methods of use thereof GOLDFINCH BIO, INC. (US) 2023-04-11 — — US disclosed
US-20210087200-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2021-03-25 — — US disclosed
US-20210087200-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2021-03-25 — — US disclosed
EP-3761989-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2021-01-13 — — EP disclosed
WO-2019173327-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-09-12 — — WO disclosed
WO-2019173327-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365575-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF REN, ATP6V1B1, GLS TRPC1 2409/4885TRPC4 1226/4885TRPC5 1332/4885
US-11623930-B2 Imidazodiazepinediones and methods of use thereof REN, ATP6V1B1, GLS TRPC1 2409/4885TRPC4 1226/4885TRPC5 1332/4885
US-20210087200-A1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF REN, ATP6V1B1, GLS TRPC1 2409/4885TRPC4 1226/4885TRPC5 1332/4885
US-12466834-B2 Imidazodiazepinediones and methods of use thereof REN, ATP6V1B1, GLS TRPC1 2409/4885TRPC4 1226/4885TRPC5 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback